NASDAQHealth CareMedical DevicesSnapshot 2026-07-23
Reading TELA? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a turnaround scenario. TELA is currently loss-making and has shown weak recent financial performance, but it operates in a healthcare sector that has a favorable momentum.
The market seems to have priced in a low level of expectations, as indicated by a significant gap in expectations. TELA is viewed as cheap compared to its peers, suggesting that investors may not be anticipating strong performance in the near term.
Management has set ambitious revenue growth targets, but recent results indicate limited progress. The near-term risk is elevated, with a 50% probability of missing expectations, especially given recent earnings misses.
The thesis hinges on TELA's ability to meet its revenue targets and the performance of sector leaders like ABT, SYK, and MDT. If these companies continue to perform well, it could provide a lift to TELA; conversely, any negative guidance from them could weigh heavily on TELA's prospects.
Over the next 1 to 3 years, TELA's performance will depend on its execution against growth targets and the overall health of the healthcare sector. Not investment advice.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: Missing earnings again could mean bigger problems in the company's operations. This might hurt investor confidence.
Confirms:Q2 2026 earnings report shows a loss or misses analyst expectations.
Disproves:The Q2 2026 earnings report meets or beats what analysts expect.
Why it matters: If revenue growth is less than 8%, it raises worries. This affects the company's yearly goals.
Confirms:Q2 2026 revenue growth reported below 8% year over year.
Disproves:Q2 2026 revenue growth reported at or above 8% year over year.
Why it matters: Meeting this target is key to achieving at least 8% growth in 2026. It shows the company is on track.
Confirms:Q2 2026 revenue reported at or above $20 million.
Disproves:Q2 2026 revenue reported below $20 million.
